Abstract
The aim of this study is to investigate whether fluorouracil (5-FU) could be responsible for bone-marrow depression occurring in fluorocytosine (5-FC) treated patients. Six 5-FC treated patients were included in this pilot study. Toxicity was monitored by means of thrombocyte and leucocyte counts. 5-FC and 5-FU serum levels were measured using a high-performance liquid chromatography (HPLC) assay that allows simultaneous determination of both compounds. The amounts of 5-FU in the 34 available serum samples remained below the limit of quantitation (< 0.05 mg/L), whereas 5-FC levels could be detected in all samples. Instead, low levels of the 5-FU catabolite alpha-fluoro-beta-alanine (FBAL) were detected in several of the investigated serum samples. In case of three patients thrombocyte counts remained within the normal range during 5-FC treatment, whereas one patient developed thrombocytopenia (50 x 10(9) thrombocytes/L) during therapy. Furthermore, one patient developed leucocytopenia (2.6 x 10(9) leucocytes/L) during 5-FC therapy, whereas the remaining five patients were suffering from leucocytosis prior to 5-FC therapy. In conclusion, we found nondetectable 5-FU serum concentrations (< 0.05 mg/L) in ICU patients treated with ...Continue Reading
References
Mar 1, 1977·Annals of Internal Medicine·J E Bennet
Mar 1, 1978·Biochemical Pharmacology·R B DiasioC E Myers
Jul 19, 1979·The New England Journal of Medicine·J E BennettD W Alling
Dec 1, 1978·Antimicrobial Agents and Chemotherapy·R B DiasioJ E Bennett
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·C A Kauffman, P T Frame
Oct 1, 1975·The Journal of Infectious Diseases·J P UtzS Shadomy
Dec 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Francis, T J Walsh
May 1, 1992·Computers in Biology and Medicine·J H Proost, D K Meijer
May 1, 1991·Infection·M C Malet-MartinoJ P Armand
Jan 1, 1986·Antimicrobial Agents and Chemotherapy·B E HarrisR B Diasio
Aug 1, 1974·The Journal of Infectious Diseases·T EilardP Wahlén
Jan 1, 1983·Drugs·J R Graybill, P C Craven
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·A R Waldorf, A Polak
Apr 1, 1981·Biomedical Mass Spectrometry·K M WilliamsP J Finlayson
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E GamelinJ Robert
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-Analysis Group In CancerP Thirion
Apr 24, 1999·Pharmacy World & Science : PWS·A VermesH J Guchelaar
Feb 15, 2000·Chemotherapy·A VermesH J Guchelaar
Aug 10, 2000·The Journal of Antimicrobial Chemotherapy·A VermesJ Dankert
Dec 29, 2000·Therapeutic Drug Monitoring·A VermesH J Guchelaar
Aug 14, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·A B Van KuilenburgA H Van Gennip
Citations
May 10, 2008·Pharmacogenomics·Joseph MeletiadisThomas J Walsh
Sep 17, 2013·Expert Opinion on Drug Metabolism & Toxicology·Mi Jeong KangHye Gwang Jeong
Feb 17, 2017·Pharmaceutical Research·Celeste AlvarezGlen S Kwon